investor_presentation
Terreno Realty Corporation
Loading viewer...
investor_presentation
Format: PDF investor_presentation
Karyopharm Therapeutics investor presentation dated March 2017.
Corporate Presentation
March 2017 2 Forward -looking Statements
•This presentation contains forward -looking statements within the meaning of the “safe harbor” provisions of The Private Securiti es Litigation Reform Act of 1995.
•Such forward -looking statements include those regarding the therapeutic potential of and potential clinical development plans an d commercialization for
Karyopharm’s drug candidates, including the timing of initiation of certain trials and of the reporting of data from such tri als, and assumptions of management
regarding strategic and financial expectations and projections.
•Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company’s
current expectations. For example, there can be no guarantee that any of Karyopharm’s SINE™ compounds, including selinexor (K PT-330) and KPT -8602,
Karyopharm’s second generation SINE™ compound, or KPT -9274, Karyopharm’s first -in-class oral dual inhibitor of PAK4 and NAMPT, o r any other drug candidate
Karyopharm is developing, will successfully complete necessary preclinical and clinical development phases, that development of any of Karyopharm’s drug
candidates will continue, or that the partial clinical hold imposed by the U.S. Food and Drug Administration on selinexor cli nical trials will be released in a timely
manner or at all. Further, there can be no guarantee that any positive developments in Karyopharm’s drug candidate portfolio will result in stock price appreciation. In
addition, even if Karyopharm receives marketing approval for selinexor or another drug candidate, there can be no assurance t hat Karyopharm will be able to
successfully commercialize that drug candidate. Management’s expectations and, therefore, any forward -looking statements in this presentation could also be
affected by risks and uncertainties relating to a number of other factors, many of which are beyond Karyopharm’s control, inc luding the following: Karyopharm’s
results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and
timing of decisions made by the FDA and other regulatory authorities, investigational review boards at clinical trial sites a nd publication review bodies; Karyopharm’s
ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash r equirements and expenditures; development of
drug candidates by Karyopharm’s competitors for diseases for which Karyopharm is currently developing its drug candidates; an d Karyopharm’s ability to obtain,
maintain and enforce patent and other intellectual property protection for any drug candidates it is developing.
•These and other risks, including those which may impact management’s expectations, are described in greater detail under the heading "Risk Factors" in
Preview truncated — download the full document for the complete content.
conference
34 Pages
investor_presentation
24 Pages
Novolipetsk Steel
investor_presentation
Terreno Realty Corporation